Playback speed
10 seconds
Adjuvant Abemaciclib + Endocrine Therapy for HR+, HER2- High-Risk eBC: Results From a Preplanned monarchE OS Interim Analysis, Including 5-Year Efficacy Outcomes
By
Insights from 2023 ESMO Annual Meeting
FEATURING
Jens Huober
By
Insights from 2023 ESMO Annual Meeting
FEATURING
Jens Huober
1,469 views
December 4, 2023
Login to view comments.
Click here to Login